Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dengue viruses (DENV1-4) are mosquito-borne flaviviruses estimated to cause up to ∼400 million infections and ∼100 million dengue cases each year. Factors that contribute to protection from and risk of dengue and severe dengue disease have been studied extensively but are still not fully understood. Results from Phase 3 vaccine efficacy trials have recently become available for one vaccine candidate, now licensed for use in several countries, and more Phase 2 and 3 studies of additional vaccine candidates are ongoing, making these issues all the more urgent and timely. At the "Summit on Dengue Immune Correlates of Protection", held in Annecy, France, on March 8-9, 2016, dengue experts from diverse fields came together to discuss the current understanding of the immune response to and protection from DENV infection and disease, identify key unanswered questions, discuss data on immune correlates and plans for comparison of results across assays/consortia, and propose a research agenda for investigation of dengue immune correlates, all in the context of both natural infection studies and vaccine trials.

Original publication

DOI

10.1016/j.vaccine.2017.07.045

Type

Conference paper

Publication Date

24/08/2017

Volume

35

Pages

4659 - 4669

Keywords

Dengue virus, Immune correlates of protection, Immune correlates of risk, Natural infection, Vaccine, Antibodies, Neutralizing, Antibodies, Viral, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Congresses as Topic, Dengue, Dengue Vaccines, Dengue Virus, Humans, Severe Dengue